Bio Medica Laboratories IPO Listing Preview 29 May 2026: Shares Credited Today, GMP Rs 0, Listing Near Issue Price Rs 139 on NSE SME

The Bio Medica Laboratories IPO shares are being credited to successful allottees’ demat accounts TODAY (27 May 2026). Allotment was finalised on 26 May 2026. Refunds to unsuccessful applicants are also being initiated today. The stock lists on NSE SME on 29 May 2026. The grey market premium has been Rs 0 throughout, the listing is expected at or near the issue price of Rs 139 per share (upper band).

Bio Medica Laboratories IPO Listing Timeline

• Allotment: 26 May 2026 (finalised)
• Shares Credit: TODAY 27 May 2026, credited to demat accounts
• Refund Initiation: TODAY 27 May 2026
• Listing Date: 29 May 2026 on NSE SME at 10 AM IST
• Issue Price: Rs 139 per share (upper band of Rs 132-139)
• Issue Size: Rs 52.43 crore (Fresh 33,95,000 + OFS 3,77,000 shares)
• GMP: Rs 0 (nil), expected listing at or near Rs 139
• Registrar: Skyline Financial Services Pvt. Ltd.
• Lead Manager: 3Dimension Capital Services Ltd.

Track Bio Medica Laboratories listing live on the .

About Bio Medica Laboratories: GMP and GLP Certified Parenteral CDMO

Bio Medica Laboratories Limited, incorporated in August 2015 in Indore, Madhya Pradesh, is a B2B pharmaceutical contract development and manufacturing organisation (CDMO) specialising in parenteral formulations. The company manufactures liquid injectables (Large Volume Parenterals and Small Volume Parenterals) and dry powder injectables for both human healthcare and veterinary segments. The facility is GMP-certified by the Madhya Pradesh FDA and GLP-certified, quality certifications that are prerequisites for supplying to regulated pharma companies. The company supplies finished pharmaceutical products to branded pharma companies across 11-plus Indian states.

• Business: B2B parenteral CDMO, liquid injectables (LVP/SVP), dry powder injectables, veterinary pharma
• Certifications: GMP (Madhya Pradesh FDA) and GLP certified
• Customers: Branded pharma companies in 11+ Indian states
• Location: Indore, Madhya Pradesh, India’s pharmaceuticals manufacturing hub
• IPO proceeds use: Rs 28.50 crore for new manufacturing unit + Rs 6.50 crore for debt repayment

Tap to Access Best Research Pieces on Univest

The CDMO Sector: Why This Model Has Structural Tailwinds

The pharmaceutical CDMO sector in India is growing at approximately 12 to 15 percent annually, driven by three converging factors: domestic pharma companies increasingly outsourcing manufacturing to reduce capital requirements, the global CDMO supply chain rebalancing away from China, and India’s CDSCO regulatory framework providing a framework for GMP-certified contract manufacturers to serve export markets over time. Indore has emerged as one of India’s fastest-growing pharma manufacturing hubs alongside Hyderabad and Ahmedabad.

Bio Medica Laboratories’ parenteral specialisation is a particularly attractive niche within the CDMO sector. Parenteral manufacturing requires sterile manufacturing capabilities, cleanroom infrastructure and strict quality controls, barriers that limit new entrants and support pricing power for certified manufacturers. The OFS component of 3,77,000 shares (approximately Rs 5.24 crore) means some selling pressure from existing shareholders at listing. For investors who received allotment, watch the first 30 minutes of trading on 29 May before making a hold or sell decision. Consult a SEBI-registered advisor before any listing day trading decision.

Disclaimer: This article is for informational and educational purposes only. Nothing in this article constitutes investment advice, a recommendation to buy or sell securities, or a solicitation of any offer to buy or sell securities. Univest is a SEBI-registered research analyst (INH000014019). Readers should conduct their own research and consult a SEBI-registered investment advisor before making any investment decisions. Past performance of any stock or sector is not indicative of future results. Investments in equity markets are subject to market risks.

FAQs on Bio Medica Laboratories IPO Listing

When does Bio Medica Laboratories list on NSE SME?

Ans. Bio Medica Laboratories IPO lists on NSE SME on 29 May 2026 at 10 AM IST. Shares are being credited to allottees’ demat accounts TODAY (27 May). Refunds are also being initiated today. GMP is Rs 0, listing expected near the issue price of Rs 139 (upper band).

What is the expected Bio Medica Laboratories IPO listing price?

Ans. Bio Medica Laboratories IPO GMP is Rs 0, indicating a listing near issue price of Rs 139 on NSE SME on 29 May. The OFS component (3,77,000 shares) may create mild selling pressure. Watch the first 30 minutes of trading on listing day before deciding to hold or sell. Consult a SEBI-registered advisor.

What does Bio Medica Laboratories do?

Ans. Bio Medica Laboratories is a B2B parenteral pharmaceutical CDMO in Indore, Madhya Pradesh. It manufactures liquid injectables (LVP and SVP) and dry powder injectables for human and veterinary segments. GMP and GLP certified. Supplies branded pharma companies in 11+ Indian states. Rs 28.50 crore of IPO proceeds fund a new manufacturing unit for capacity expansion.